Guttman Institute Reopens With Expanded Screening Services

Oncology NEWS InternationalOncology NEWS International Vol 5 No 9
Volume 5
Issue 9

NEW YORK--The Guttman Institute, a pioneering breast cancer screening center in Manhattan that provided low-cost screenings to women for almost 30 years, has become a cancer diagnostic center serving both men and women.

NEW YORK--The Guttman Institute, a pioneering breast cancer screeningcenter in Manhattan that provided low-cost screenings to womenfor almost 30 years, has become a cancer diagnostic center servingboth men and women.

Memorial Sloan-Kettering Cancer Center acquired the Guttman Institutein January of this year, renovated and expanded the facility,and reopened it last July as the Memorial Sloan-Kettering GuttmanDiagnostic Center. The formerly pink-walled center once decoratedsolely with women in mind, emerged from renovations with a wood-paneledexecutive boardroom look and coed staff.

The new Guttman offers cervical, prostate, and colorectal screeningsas well as enhanced breast cancer detection, including ultrasound,ultrasound-guided biopsy, and fine-needle aspirations.

The Guttman Center will continue to carry on the renowned workof Dr. Philip Strax, the Institute's founder and original medicaldirector, Michael A. Cohen, MD, the new medical director, saidat the official reopening.

Dr. Strax was the principle investigator of the landmark 1963Health Insurance Plan (HIP) of Greater New York trial, the firstrandomized controlled study designed to prove the efficacy ofmammography screening, Dr. Cohen said. The HIP study showed a30% reduction in women receiving yearly mam-mography and breastphysical examinations over those who received neither.

The women who were first enrolled in the study became the patientsof the Guttman Institute when Dr. Strax founded it in 1968, Dr.Cohen noted. "His study literally christened mammographyas a legitimate screening modality."

The HIP trial still has relevance to issues facing today's oncologistsand radiologists, such as whether to screen women between theages of 40 and 49 for breast cancer, Dr. Cohen added.

Dr. Strax's study revealed a reduction in mortality among women40 to 49 who had been screened, but due to the small numbers,the findings were not significant. However, a later review ofthe data did confirm a statistically significant 24% mortalityreduction in the screened women in that age group, a statisticthat is similar to the findings of recent studies.

Dr. Cohen noted that the NCI, which withdrew its support for mammographicscreening for women between 40 to 49 years of age in 1993, willbe convening a consensus conference in early 1997 to reconsidertheir position in light of new data from a variety of studies."It would appear to me that once these data are analyzed,the NCI will have little choice but to support some program forscreening women 40 to 49," he said.

A Dramatic Entrance

As Dr. Cohen concluded his remarks, the elevator door opened inthe wood-paneled Guttman Center lobby and a man in a bright greenblazer got out. Dr. Philip Strax, who had just arrived from hishome in Florida, looked around and pronounced the new center "wonderful."

Dr. Strax recalled how his friend Charles Guttman, who grew upon New York City's Lower East Side and became a successful businessmanand philanthropist, had agreed to help him start his institute."Charley had the dough. He set up the finances, and we showedwith the HIP study that early detection saves lives," Dr.Strax said.

Related Videos
The August CancerNetwork Snap Recap takes a look back at key FDA news updates, as well as expert perspectives on the chemotherapy shortage.
Ann H. Partridge, MD, MPH, talks about how fertility preservation can positively impact the psychosocial health in patients with breast cancer.
Daniel G. Stover, MD, describes how findings from the phase 3 NATALEE trial may support expanding the portion of patients who receive CDK 4/6 inhibitors as a treatment for hormone receptor–positive, HER2-negative breast cancer.
Daniel G. Stover, MD, suggests that stromal tumor infiltrating lymphocytes may serve as a biomarker of immune activation and can potentially help optimize therapy with microtubule-targeting agents for patients with metastatic breast cancer.
Sara M. Tolaney, MD, MPH, discusses how, compared with antibody-drug conjugates, chemotherapy produces low response rates and disease control in the treatment of those with hormone receptor–positive, HER2-negative metastatic breast cancer.
Hope Rugo, MD, speaks to the importance of identifying patients with aromatase inhibitor–resistant, hormone receptor–positive, HER2-negative advanced breast cancer who are undergoing treatment with capivasertib/fulvestrant who may be at a high risk of developing diabetes or hyperglycemia.
Sara M. Tolaney, MD, MPH, describes the benefit of sacituzumab govitecan for patients with HER2-low metastatic breast cancer seen in the final overall survival analysis of the phase 3 TROPiCS-02 study.
An expert from Dana-Farber Cancer Institute describes which patients hormone receptor-positive,  HER2-negative breast cancer will benefit most from treatment with sacituzumab govitecan.
An expert from Dana-Farber Cancer Institute highlights the unmet needs that sacituzumab govitecan meets in the treatment of advanced hormone receptor-positive, HER2-negative breast cancer.
An expert from Dana-Farber Cancer Institute highlights data that supported the FDA’s approval of sacituzumab govitecan for advanced hormone receptor–positive, HER2-negative breast cancer.
Related Content